Please check your internet connection and try again.
# Montelukast-Levocetirizine
## Overview
A fixed-dose combination (FDC) of a leukotriene receptor antagonist (montelukast) and a second-generation H1-receptor antagonist (levocetirizine). This combination provides dual-pathway inhibition of the allergic cascade by addressing both histamine release and leukotriene-mediated inflammation.
## Primary Indications
* Allergic rhinitis (AR)
* Rhinitis associated with asthma
* Chronic urticaria (off-label use of combination)
## Adult Dosing
* **Standard dose:** Montelukast 10 mg / Levocetirizine 5 mg administered orally once daily, typically in the evening.
## Pediatric Dosing
* **Age 6–11 years:** Montelukast 5 mg / Levocetirizine 2.5 mg once daily.
* **Age <6 years:** Not typically available as a fixed-dose combination; monotherapy or weight-based liquid formulations are preferred.
* *Note:* Always verify specific product labeling, as FDC availability varies by region and manufacturer.
## Dose Adjustments
* **Renal Impairment:** Levocetirizine requires dose reduction or interval modification in patients with CrCl <50 mL/min per package insert (e.g., 2.5 mg daily for CrCl 30–50 mL/min). Adjustments for montelukast are not typically required.
* **Hepatic Impairment:** No specific adjustment required for montelukast, but monitor for rare drug-induced liver injury.
## Contraindications
* Hypersensitivity to montelukast, levocetirizine, or cetirizine.
* End-stage renal disease (CrCl <10 mL/min) or patients undergoing dialysis (for levocetirizine component).
## Adverse Effects
* **Common:** Somnolence, fatigue, headache, xerostomia (dry mouth), and pharyngitis.
* **Serious:** Neuropsychiatric events (aggression, agitation, depression, suicidal ideation) associated with montelukast; urge practitioners to screen for mood changes.
## Key Drug Interactions
* **CNS Depressants:** May potentiate sedative effects of levocetirizine (alcohol, opioids, benzodiazepines).
* **CYP450 Inducers:** Phenobarbital or phenytoin may decrease serum concentrations of montelukast.
* **Ritonavir:** May increase plasma concentrations of levocetirizine.
## Monitoring
* **Psychiatric:** Monitor for changes in behavior or mood in patients taking montelukast.
* **Renal:** Monitor serum creatinine in patients with baseline renal impairment.
* **Efficacy:** Monitor for reduction in sneezing, rhinorrhea, and nasal congestion.
## Clinical Pearls
* **Timing:** Administration in the evening is preferred in many protocols to provide better coverage for nocturnal and early-morning allergic symptoms and to mitigate daytime somnolence from levocetirizine.
* **FDA Warning:** The FDA requires a "Boxed Warning" for montelukast regarding serious neuropsychiatric events. The drug should only be used for allergic rhinitis if other treatments are ineffective or not tolerated.
* **Benefit:** The combination is often more effective than monotherapy for patients with moderate-to-severe allergic rhinitis who have not achieved adequate control with antihistamines alone.
***
**Educational Disclaimer:** This information is for educational purposes and does not constitute medical advice. Clinical protocols vary by region and institution. Prescribers must verify current prescribing information, contraindications, and local drug availability via official product monographs or clinical references (e.g., Lexicomp, UpToDate) before ordering.
